Oppenheimer analyst Jay Olson said he is encouraged by the results of Phase 3 REGENERATE study of OCA in NASH and believes that fibrosis improvement should support FDA registration. Following the data report, Olson increased his potential for success odds to 90% from 75% for OCA in NASH and raised his price target on Intercept shares to $175 while keeping an Outperform rating on the stock.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.